Topical Application of Tranexamic Acid in Primary Total Hip Arthroplasty: A Randomized Double-Blind Controlled Trial

• Published in: The Journal of arthroplasty Vol. 29; no. 12; pp. 2452 - 2456
• Main Authors: Yue, Chen, MD, Kang, Pengde, MD, Yang, Peiqing, MD, Xie, Jinwei, MD, Pei, Fuxing, MD
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01-12-2014
• Subjects: Administration, Topical; Aged; Antifibrinolytic Agents - administration & dosage; Arthroplasty, Replacement, Hip - adverse effects; blood loss; Blood Transfusion; Double-Blind Method; DVT; Female; Humans; Male; Middle Aged; Orthopedics; Postoperative Hemorrhage - etiology; Postoperative Hemorrhage - prevention & control; THA; topical; tranexamic acid; Tranexamic Acid - administration & dosage; transfusions; topical; DVT; THA; blood loss; transfusions; tranexamic acid
• ISSN: 0883-5403; 1532-8406
• DOI: 10.1016/j.arth.2014.03.032

Abstract So far, studies of topical tranexamic acid (TXA) in total hip arthroplasty (THA) were still lacking and controversial. We conducted this randomized double-blind controlled trial which included 101 patients to assess the effect of a high-dose 3 g topical TXA in THA. The results showed that 3 g topical TXA could significantly reduce transfusions from 22.4% to 5.7% ( P < 0.05) without increasing the risk of deep vein thrombosis (DVT), pulmonary embolism (PE) and other complications. In addition, topical TXA significantly reduced total blood loss, reduced drain blood loss, and the drops of HB and HCT in topical TXA group were lower than control group. We concluded that 3 g topical TXA was effective and safe in reducing bleeding and transfusions in THA.